NCT02060266View on ClinicalTrials.gov

Trial Investigating the Absorption, Metabolism and Excretion After a Single Subcutaneous Dose of [3H]-Semaglutide in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

7

Participants

Timeline

Start Date

February 4, 2014

Primary Completion Date

April 28, 2014

Study Completion Date

April 28, 2014

Conditions

DiabetesHealthy

Interventions

DRUG

semaglutide

Subjects will receive a single dose subcutaneously (s.c., under the skin).

Trial Locations (1)

9728 NZ

Novo Nordisk Investigational Site, Groningen

Sponsors

Lead Sponsor

Novo Nordisk A/S

All Listed Sponsors

lead

Novo Nordisk A/S

INDUSTRY

NCT02060266 - Trial Investigating the Absorption, Metabolism and Excretion After a Single Subcutaneous Dose of [3H]-Semaglutide in Healthy Male Subjects | Biotech Hunter | Biotech Hunter